Summit Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Summit Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$5.79M	Sell	66,621 -894	-1%	-$79.9K	2.62%	9
2015 Q4	$7.61M	Buy	67,515 +1,089	+2%	+$118K	3.08%	7
2015 Q3	$6.72M	Sell	66,426 -62,268	-48%	-$7.47M	3.28%	7
2015 Q2	$15.8M	Buy	128,694 +5,556	+5%	+$665K	6.75%	3
2015 Q1	$14.1M	Buy	123,138 +1,893	+2%	+$209K	5.68%	3
2014 Q4	$12.3M	Buy	121,245 +7,137	+6%	+$694K	4.59%	5
2014 Q3	$10.4M	Buy	+114,108	New	+$10M	3.68%	4
2014 Q2	–	Sell	-115,164	Closed	-$9.07M	–	58
2014 Q1	$9.07M	Buy	115,164 +11,652	+11%	+$971K	3.21%	7
2013 Q4	$7.83M	Buy	+103,512	New	+$7.34M	2.95%	6

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Summit Capital Management's IBB Position: Q1 2016 in Review

Summit Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 1.3% in Q1 2016, selling an estimated $79.9K and leaving 66,621 shares worth $5.79M. The position accounts for 2.62% of the portfolio, ranked #9.

Summit Capital Management first reported a position in IBB in Q4 2013 and has held it in 9 quarters since. The position peaked at $15.8M in Q2 2015. 415 funds tracked by Wall St. Rank hold IBB as of Q1 2016.

Summit Capital Management held 66,621 shares of iShares Biotechnology ETF worth $5.79M as of Q1 2016.
Summit Capital Management sold 894 iShares Biotechnology ETF shares in Q1 2016, an estimated $79.9K.
iShares Biotechnology ETF made up 2.62% of Summit Capital Management's portfolio in Q1 2016, its #9 holding.
Summit Capital Management first reported a position in iShares Biotechnology ETF in Q4 2013 and has held it in 9 quarters since.
Summit Capital Management's iShares Biotechnology ETF position peaked at $15.8M in Q2 2015.
415 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2016.

Based on Summit Capital Management's 13F filing for Q1 2016, filed 11 May 2016.